Scientists at MELISA Institute work relying on cutting edge laboratory technologies in immunoassay, proteomics and genomics that enable us to research on the causes affecting maternal, embryonic and fetal health, thus working on developing therapeutic options that improve or restore maternal, embryonic or fetal health from early stages of pregnancy.
Through mass spectrometry techniques applied to proteomics such 35 LFQ (Label-free quantification), and TMT (Tandem M355 Tag) we can elucidate in different biological fluids the signals of communication between the human embryo and its mother. Highly specific therapeutics can be achieved by studying cell signaling through proteins and biological trophic factors. Protein identification and quantification are crucial to identify unknown compounds produced during the early stages of embryo development. We achieve this through the use of cutting-edge mass spectrometry.
GENOMICS AND NEXT-GENERATION SEQUENCING
At the MELISA Institute, we work with the latest techniques in DNA / RNA sequencing (next-generation sequencing), which opens up our research capabilities in very detailed and specific regions of the human genome and transcriptome. This biomedical research approach opens a paradigm of personalized maternal-embryonic health research through precision medicine.
CLINICAL SAMPLE BIOREPOSITORY
Our clinical team collects tissue samples that are securely receipt, processed, and stored in our state of the art Biorepository, allowing our team of researchers to work with samples that will help us advance new breakthrough discoveries that will impact the wellbeing of patients.
Sample integrity is essential for laboratory research best practices. Our cold storage unit is equipped with -80 °C freezer banks and liquid nitrogen storage tanks, currently providing our Biorepository with the capacity of preserving 1,400 liters of samples.